Literature DB >> 23118468

Unrealistic optimism and the ethics of phase I cancer research.

Joshua Crites1, Eric Kodish.   

Abstract

One of the most pressing ethical challenges facing phase I cancer research centres is the process of informed consent. Historically, most scholarship has been devoted to redressing therapeutic misconception, that is, the conflation of the nature and goals of research with those of therapy. While therapeutic misconception continues to be a major ethical concern, recent scholarship has begun to recognise that the informed consent process is more complex than merely a transfer of information and therefore cannot be evaluated only according to how well an individual understands such information. Other components of decision-making operate independently of understanding and yet still may compromise the quality of informed consent. Notable among these components is unrealistic optimism, an event-specific belief that one has a better chance of receiving benefit than others similarly situated. In this article, we consider responses to interviews with parents who had recently completed an informed consent conference for enrolling their child in a phase I cancer clinical trial to examine how this influence manifests and how investigators might address it during informed consent.

Entities:  

Keywords:  Research Ethics

Mesh:

Year:  2012        PMID: 23118468      PMCID: PMC3697015          DOI: 10.1136/medethics-2012-100752

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  14 in total

1.  Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism.

Authors:  Sam Horng; Christine Grady
Journal:  IRB       Date:  2003 Jan-Feb

2.  Therapeutic misconception and the appreciation of risks in clinical trials.

Authors:  Charles W Lidz; Paul S Appelbaum; Thomas Grisso; Michelle Renaud
Journal:  Soc Sci Med       Date:  2004-05       Impact factor: 4.634

Review 3.  Optimistic biases about personal risks.

Authors:  N D Weinstein
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

4.  The problem with optimism in clinical trials.

Authors:  Lynn A Jansen
Journal:  IRB       Date:  2006 Jul-Aug

5.  Quality of informed consent in cancer clinical trials: a cross-sectional survey.

Authors:  S Joffe; E F Cook; P D Cleary; J W Clark; J C Weeks
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

6.  Unrealistic optimism and the Health Belief Model.

Authors:  V A Clarke; H Lovegrove; A Williams; M Machperson
Journal:  J Behav Med       Date:  2000-08

7.  The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a Phase I cancer clinical trial.

Authors:  L Cohen; C de Moor; R J Amato
Journal:  Cancer       Date:  2001-05-15       Impact factor: 6.860

8.  Communicating and understanding the purpose of pediatric phase I cancer trials.

Authors:  Melissa K Cousino; Stephen J Zyzanski; Amy D Yamokoski; Rebecca A Hazen; Justin N Baker; Robert B Noll; Susan R Rheingold; J Russell Geyer; Stewart C Alexander; Dennis Drotar; Eric D Kodish
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

9.  Informed consent: study of quality of information given to participants in a clinical trial.

Authors:  N Lynöe; M Sandlund; G Dahlqvist; L Jacobsson
Journal:  BMJ       Date:  1991-09-14

10.  Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent.

Authors:  Kevin P Weinfurt; Damon M Seils; Janice P Tzeng; Kate L Compton; Daniel P Sulmasy; Alan B Astrow; Nicholas A Solarino; Kevin A Schulman; Neal J Meropol
Journal:  Med Decis Making       Date:  2008-03-31       Impact factor: 2.583

View more
  10 in total

Review 1.  Getting personal: Head and neck cancer management in the era of genomic medicine.

Authors:  Andrew C Birkeland; Wendy R Uhlmann; J Chad Brenner; Andrew G Shuman
Journal:  Head Neck       Date:  2015-08-13       Impact factor: 3.147

2.  Ethical Challenges in Pediatric Oncology Care and Clinical Trials.

Authors:  Daniel J Benedetti; Jonathan M Marron
Journal:  Recent Results Cancer Res       Date:  2021

3.  Study partners perform essential tasks in dementia research and can experience burdens and benefits in this role.

Authors:  Betty S Black; Holly A Taylor; Peter V Rabins; Jason Karlawish
Journal:  Dementia (London)       Date:  2016-05-13

4.  Ways of Hoping: Navigating the Paradox of Hope and Despair in Chronic Pain.

Authors:  Emery R Eaves; Mark Nichter; Cheryl Ritenbaugh
Journal:  Cult Med Psychiatry       Date:  2016-03

Review 5.  The complexity of consenting to clinical research in phase I pediatric cancer studies.

Authors:  Tal Schechter; Ronald Grant
Journal:  Paediatr Drugs       Date:  2015-02       Impact factor: 3.022

6.  Clinician perspectives on communication and implementation challenges in precision oncology.

Authors:  Jada G Hamilton; Smita C Banerjee; Sigrid V Carlsson; Jacqueline Vera; Kathleen A Lynch; Lili Sar-Graycar; Chloé M Martin; Patricia A Parker; Jennifer L Hay
Journal:  Per Med       Date:  2021-10-22       Impact factor: 2.119

7.  Hope and persuasion by physicians during informed consent.

Authors:  Victoria A Miller; Melissa Cousino; Angela C Leek; Eric D Kodish
Journal:  J Clin Oncol       Date:  2014-09-08       Impact factor: 44.544

8.  Parental Experiences of Child Participation in a Phase I Pediatric Oncology Clinical Trial: "We Don't Have Time to Waste".

Authors:  Stacey Crane; Joan E Haase; Susan E Hickman
Journal:  Qual Health Res       Date:  2018-04-11

9.  Communication about the risks and benefits of phase I pediatric oncology trials.

Authors:  Rebecca A Hazen; Stephen Zyzanski; Justin N Baker; Dennis Drotar; Eric Kodish
Journal:  Contemp Clin Trials       Date:  2015-01-29       Impact factor: 2.226

10.  The role of therapeutic optimism in recruitment to a clinical trial in a peripartum setting: balancing hope and uncertainty.

Authors:  Nina Hallowell; Claire Snowdon; Susan Morrow; Jane E Norman; Fiona C Denison; Julia Lawton
Journal:  Trials       Date:  2016-06-01       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.